Dr. Vinay Prasad succeeds Dr. Peter Marks, who left the role of leader of the FDA’s Center for Biologics Evaluation and ...

Moderna Inc. shares declined after the company’s first-quarter vaccine sales missed estimates and it disclosed a delay in the ...

The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA leadership and ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Moderna (MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

The Food and Drug Administration announced Tuesday it has picked a new head of its center charged with vaccine approvals and other biologics products: Dr. Vinay Prasad, a vocal critic of the agency's ...

The Trump administration's unprecedented $500 million grant for a broadly protective flu shot has confounded vaccine and ...

WASHINGTON (AP) — Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, ...

The Food and Drug Administration has tapped Vinay Prasad, a prominent critic of federal COVID-19 policies and a proponent of ...